Abstract: OBJECTIVE To systematically evaluate the clinical efficacy and safety of moxifloxacin combined with capreomycin in treatment of patients with multi-drug resistant pulmonary tuberculosis(MDR-PTB). METHODS China national knowledge infrastructure(CNKI), China biology medicine(CBM), VIP, WanFang database, PubMed, EMbase, Cochrane Library was searched by computer. Randomized controlled trial(RCT) of moxifloxacin combined with capreomycin in treating MDR-PTB were included before the deadline of December 2018. According to the inclusive and exclusive criteria, the literatures and data were independently screened and extracted by two researchers, meanwhile the quality of the included studies were assessed. Meta-analysis was conducted by RevMan 5.2 software. RESULTS A total of fifteen RCTs including 1 417 patients. Meta-analysis showed that the total clinical effective rate, cavity closure rate, focus absorption rate and sputum bacteria negative conversion rate in moxifloxacin combined with capreomycin group were superior to the control group, the difference was statistically significant(P<0.05). The adverse reactions in treatment group could be recovered after symptomatic treatment without significant differences compared with control group. CONCLUSION The current evidence indicates that moxifloxacin combined with capreomycin have a better effect in treating patients with MDR-PTB in China, and it can effectively promote cavity closure and lesion absorption, improve sputum bacteria negative conversion rate with no significance in adverse effect.